Advanced Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Not yet recruiting
  • Advanced Lymphoma
  • +13 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +2 more
  • (no location specified)
2022-03-30
Mar 30, 2022
C
Not yet recruiting
  • Advanced Solid Tumor
  • Advanced Lymphoma
  • New York, New York
  • +1 more
2022-03-14
Mar 14, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Afatinib Dimaleate
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Trametinib Dimethyl Sulfoxide
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Trastuzumab Emtansine
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • PI3K-beta Inhibitor GSK2636771
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +4 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Dabrafenib Mesylate
  • Trametinib Dimethyl Sulfoxide
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Trametinib Dimethyl Sulfoxide
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Defactinib Hydrochloride
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • PI3K-beta Inhibitor GSK2636771
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
A
Recruiting
  • Advanced Solid Tumor
  • Advanced Lymphoma
  • AN4005-dose level 0
  • +5 more
  • Hackensack, New Jersey
    Hackensack University Medical Center
2021-10-13
Oct 13, 2021
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Trametinib Dimethyl Sulfoxide
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2021-07-23
Jul 23, 2021
S
Recruiting
  • Advanced Solid Tumor
  • Advanced Lymphoma
  • Denver, Colorado
  • +3 more
2021-07-03
Jul 3, 2021
N
Completed
  • Advanced Lymphoma
  • +5 more
  • FGFR Inhibitor AZD4547
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2021-06-08
Jun 8, 2021
N
Completed
  • Advanced Lymphoma
  • +5 more
  • Nivolumab
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2021-03-15
Mar 15, 2021
N
Withdrawn
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2020-07-17
Jul 17, 2020
M
Recruiting
  • Advanced Lymphoma
  • +4 more
  • Next generation functional drug screening
  • Comprehensive genomic profiling
  • Vienna, Austria
    Medical University of Vienna
2020-07-10
Jul 10, 2020